Prostate Cancer
Adding Custirsen to Docetaxel Retreatment/Prednisone as Second Line Therapy in Men With CRPC (20092378)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment / Prednisone as an Option for Second-line Therapy in Men with Castrate Resistant Prostate Cancer
Investigator: Tia Higano, MD; Conditions: Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer; Status: Recruiting; Study ID: NCT01083615
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Investigator: ; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT00567580
A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
Investigator: Dr. Celestia S. Higano; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01212991
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone
Investigator: Fred Appelbaum, MD; Conditions: Metastatic Cancer, Prostate Cancer; Status: Recruiting; Study ID: NCT00079001
Molecular correlates of sensitivity and resistance to therapy in prostate cancer
Investigator: Robert Montgomery, MD; Conditions: Metastatic Prostate Cancer; Status: Recruiting; Study ID: NCT01050504
Canary Prostate Active Surveillance Study
Investigator: Daniel W. Lin, MD; Conditions: Prostatic Neoplasms; Status: Recruiting; Study ID: NCT00756665
SCORE -- Assessment of Mood, Information Processing and Quality of Life in Prostate Cancer Survivors and Patients
Investigator: Monique Cherrier, PhD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: 30824
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Investigator: Dr. Celestia S. Higano; Conditions: Advanced Solid Tumors; Status: Recruiting; Study ID: NCT00940225
A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer
Investigator: Tia Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT00488982
A Randomized Phase II Study of Combined Androgen Deprivation Versus Combined Androgen Deprivation with IMC-A12 for Patients with New Hormone Sensitive Metastatic Prostate Cancer
Investigator: Evan Yu, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01120236
Phase 2 Trial of Radiation with Androgen Deprivation (RAD): Abiraterone Acetate, Prednisone and LHRH Agonist Prior to and Concurrent with Radiation Therapy.
Investigator: Robert Montgomery, MD; Conditions: Prostate Cancer, Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer; Status: Recruiting; Study ID: NCT01023061
Intermittent Hormone Therapy in Men with Localized Prostate Cancer who Have Biochemical Relapse After External Beam Irradiation or Radical Prostatectomy
Investigator: Tia Higano, MD; Conditions: Genitourinary Cancer; Prostate Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT00223665
A Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, or No MLN8237 in Patients with Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel/Prednisone Regimen, Preceded by a Phase I Dose-Escalation Study - Part 1 and 2
Investigator: Tia Higano, MD; Conditions: Genitourinary Cancer; Prostate Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01094288
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Not Recruiting; Study ID: NCT01063816
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Investigator: John Thompson, MD; Conditions: Advanced Non-Hematologic Malignancies, Non Small Cell Lung Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Prostate Cancer; Status: Recruiting; Study ID: NCT00830869
Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II
Investigator: Fred Appelbaum, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01309672
Join Us On